📰 Expanded Access Program News

Page 17 - Expanded Access Program News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Expanded Access Program. Real-time updates on events, politics, business and more.

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

March 17, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational...

United Arab Emirates United States South Korea United Kingdom South Africa Saudi Arabia

Source: prnewswire.com

MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting

March 17, 2022

Data from 76 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013 will be presented. Oral presentation will highlight MaaT013's potential in improving survival outcome for

United States Microbiotherapy Maa Florent Malard Drug Administration Early Access Program Trophic Communications

Source: finanznachrichten.de

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

February 17, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided a business update for...

Amber Fennell Dror Ben Asher Redhill Biopharma Adi Frish International Financial Reporting Standards Redhill Biopharma Ltd

Source: prnewswire.com

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

February 17, 2022

TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. , a specialty biopharmaceutical company, today provided a business update for the fourth quarter of... | February 17, 2022

Amber Fennell Dror Ben Asher Redhill Biopharma Adi Frish International Financial Reporting Standards Redhill Biopharma Ltd

Source: marketscreener.com

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer

February 15, 2022

/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration...

Priyanka Shah Charles Baum Temre Johnson Prnewswire Mirati Therapeutics Inc Thoracic Oncology At Dana Farber Cancer Institute Drug Administration

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer

February 15, 2022

/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration...

Priyanka Shah Charles Baum Temre Johnson Prnewswire Mirati Therapeutics Inc Thoracic Oncology At Dana Farber Cancer Institute Drug Administration

Source: prnewswire.com

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

February 7, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two...

United Kingdom Amber Fennell Redhill Biopharma Adi Frish Mark Levitt Us National Institute Of Health

Source: prnewswire.com

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

February 7, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two...

United Kingdom Amber Fennell Redhill Biopharma Adi Frish Mark Levitt Us National Institute Of Health

Source: prnewswire.com